Vice President, Marketing

Who we are:Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit  or follow us on X (formerly Twitter) or LinkedIn. How we work:PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.How you’ll make an impact: As we prepare for the potential launch of KT-621, a novel oral protein degrader being developed for immune-mediated diseases, we are seeking an experienced and strategic leader to prepare the organization for Kymera’s first commercial launch.  The position will be responsible for leading commercial strategy, launch readiness, and brand planning activities for KT-621. Reporting directly to the Chief Commercial Officer, this individual will play a pivotal leadership role in shaping the commercial vision, product positioning, customer strategy, launch preparation and launch for one of the most important assets in Kymera's portfolio.  The successful candidate will bring deep immunology expertise, including direct experience in atopic dermatitis and preferably asthma, along with a demonstrated track record of leading successful commercialization efforts for innovative therapies.  Lead development and execution of the global commercial strategy for KT-621 from late-stage development through launch and lifecycle management.  Define the global product vision, positioning, differentiation, target patient segments, and value proposition.  Lead U.S. launch readiness planning and all commercialization activities.  Develop disease-state and product-specific marketing strategies and messaging.  Partner closely with the Analytics & Insights function on competitive intelligence, market assessments, forecasting inputs, and customer research.  Serve as the commercial lead within cross-functional development teams.  Influence clinical development strategy, endpoint selection, and evidence-generation plans.  Evaluate expansion opportunities across immunology indications. Build strong partnerships across Clinical Development, Medical Affairs, Market Access, Regulatory, Finance, and Executive Leadership.  Skills and experience you’ll bring: Advanced degree required (MBA, PharmD, PhD, MD, MPH, or equivalent).  15+ years of progressive pharmaceutical or biotechnology commercial experience spanning U.S. and global markets.  Significant experience in marketing, commercial strategy, and launch planning.  Direct immunology experience required.  Direct atopic dermatitis experience required.  Asthma experience preferred.  Demonstrated success leading products through late-stage development and particularly US commercial launch.  Strong understanding of specialty physician markets, payer dynamics.  Leadership Competencies  Strategic thinker with strong commercial acumen  Exceptional communication and executive presence  Proven ability to influence cross-functional teams  Data-driven decision maker  Strong team builder and talent developer  Results-oriented with a demonstrated ability to execute  This is a unique opportunity to lead the commercialization strategy for KT-621, a potentially transformative oral protein degrader that could redefine treatment paradigms across immunology. Equal Employment OpportunityKymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.CompensationKymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.The anticipated base salary range for this role is $315,000 – $395,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.